TY - JOUR

T1 - Parathyroideahormonrelateret peptid-induceret humoral hyperkalkæmi ved malignitet

AU - Tfelt-Hansen, Jacob

AU - Brixen, Kim T.

AU - Mosekilde, Leif

AU - Schwarz, Peter

PY - 2005/2/21

Y1 - 2005/2/21

N2 - Humoral hypercalcaemia of malignancy (HHM) is defined by a tumor producing hypercalcemia through a systemic hormone or cytokine. In approximately 80% of HHM cases, parathyroid hormone-related peptide (PTHrP) is the causal factor. Primary hyperparathyroidism (PHPT) and metastasis to the bone are the most important differential diagnoses. The treatment strategy in cases of HHM is to decrease the serum calcium by fluid, loop diuretics, glucorticoids and bisphosphonate. Moreover, the underlying malignant disease should be treated. The prognosis for patients with HHM, however, is poor.

AB - Humoral hypercalcaemia of malignancy (HHM) is defined by a tumor producing hypercalcemia through a systemic hormone or cytokine. In approximately 80% of HHM cases, parathyroid hormone-related peptide (PTHrP) is the causal factor. Primary hyperparathyroidism (PHPT) and metastasis to the bone are the most important differential diagnoses. The treatment strategy in cases of HHM is to decrease the serum calcium by fluid, loop diuretics, glucorticoids and bisphosphonate. Moreover, the underlying malignant disease should be treated. The prognosis for patients with HHM, however, is poor.

UR - http://www.scopus.com/inward/record.url?scp=14844304289&partnerID=8YFLogxK

M3 - Review

C2 - 15789851

AN - SCOPUS:14844304289

VL - 167

SP - 924

EP - 926

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 8

ER -